Maksuda Hossain

Maksuda Hossain

Auto-generated profile, based on publicly available information

Maksuda Hossain

Center for Immunotherapy, Vaccines, and Virotherapy, Biodesign Institute, Arizona State University, Tempe, Arizona

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2023 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
MRMasmudur Rahman
Masmudur Rahman
FOFleur van Oosterom
Fleur van Oosterom
JEJunior Ayuk Enow
Junior Ayuk Enow
MHMaksuda Hossain
Maksuda Hossain
AGAmi Gutierrez-Jensen
Ami Gutierrez-Jensen
GMGrant McFadden
Grant McFadden
Oncolytic viruses exploited for cancer therapy have been developed to selectively infect, replicate, and kill cancer cells to inhibit tumor growth. However, in some cancer cells, oncolytic viruses are often limited in completing their full replication cycle, forming progeny virions, and/or spreading in the tumor bed because of the heterogeneous cell types within the tumor bed. Here, we report that the nuclear export pathway regulates oncolytic myxoma virus (MYXV) infection and cytoplasmic viral replication in a subclass of human cancer cell types where viral replication is restricted. Inhibition of the XPO-1 (exportin 1) nuclear export pathway with nuclear export inhibitors can overcome this restriction by trapping restriction factors in the nucleus and allow significantly enhanced viral replication and killing of cancer cells. Furthermore, knockdown of XPO-1 significantly enhanced MYXV replication in restrictive human cancer cells and reduced the formation of antiviral granules associated with RNA helicase DHX9. Both in vitro and in vivo, we demonstrated that the approved XPO1 inhibitor drug selinexor enhances the replication of MYXV and kills diverse human cancer cells. In a xenograft tumor model in NSG mice, combination therapy with selinexor plus MYXV significantly reduced the tumor burden and enhanced the survival of animals. In addition, we performed global-scale proteomic analysis of nuclear and cytosolic proteins in human cancer cells to identify the host and viral proteins that were upregulated or downregulated by different treatments. These results indicate, for the first time, that selinexor in combination with oncolytic MYXV can be used as a potential new therapy. Significance: We demonstrated that a combination of nuclear export inhibitor selinexor and oncolytic MYXV significantly enhanced viral replication, reduced cancer cell proliferation, reduced tumor burden, and enhanced the overall survival of animals. Thus, selinexor and oncolytic MYXV can be used as potential new anticancer therapy.

16 May 2023
Verified
Other
Open access
MRMasmudur Rahman
Masmudur Rahman
FOFleur van Oosterom
Fleur van Oosterom
JEJunior Ayuk Enow
Junior Ayuk Enow
MHMaksuda Hossain
Maksuda Hossain
AGAmi Gutierrez-Jensen
Ami Gutierrez-Jensen
GMGrant McFadden
Grant McFadden
Tumor burden of individual mouse received Colo205 cells.

1 June 2023
Verified
Other
Open access
MRMasmudur Rahman
Masmudur Rahman
FOFleur van Oosterom
Fleur van Oosterom
JEJunior Ayuk Enow
Junior Ayuk Enow
MHMaksuda Hossain
Maksuda Hossain
AGAmi Gutierrez-Jensen
Ami Gutierrez-Jensen
GMGrant McFadden
Grant McFadden
Tumor burden of individual mouse received PANC-1 cells.

1 June 2023
Verified
Other
Open access
MRMasmudur Rahman
Masmudur Rahman
FOFleur van Oosterom
Fleur van Oosterom
JEJunior Ayuk Enow
Junior Ayuk Enow
MHMaksuda Hossain
Maksuda Hossain
AGAmi Gutierrez-Jensen
Ami Gutierrez-Jensen
GMGrant McFadden
Grant McFadden
LMB treatment significantly enhanced MYXV replication in human cancer cells by reducing the formation of DHX9 antiviral granules. PANC-1 (A) and HT29 (B) cells were treated with different concentration of LMB for 1 hour, infected with different MOI of vMyx-GFP-TdTomato for 1 hour and replaced with fresh media containing the same doses of LMB. Fluorescence images were taken 48 hpi. PANC-1 (C) and HT29 (D) cells were harvested at different timepoints to determine progeny virus production by titration assays on permissive RK13 cells. Data represent mean ± SD and n = 3. Statistically significant differences in comparison with infection without LMB are indicated. E, A549 cells were treated with the indicated concentration of LMB for 1 hour and infected with vMyx-GFP (MOI = 1.0). After 24 hpi, the cells were fixed and stained with antibodies against DHX9. Nuclei were stained with DAPI and imaged by fluorescence microscope. F, Number of cells showing strong nuclear or cytoplasmic staining of DHX9 after 24 hpi. A minimum of 100 cells were used for analysis from fluorescence images taken in E. Data represent mean ± SD and n = 3. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.

16 May 2023
Verified
Other
Open access
MRMasmudur Rahman
Masmudur Rahman
FOFleur van Oosterom
Fleur van Oosterom
JEJunior Ayuk Enow
Junior Ayuk Enow
MHMaksuda Hossain
Maksuda Hossain
AGAmi Gutierrez-Jensen
Ami Gutierrez-Jensen
GMGrant McFadden
Grant McFadden
Oncolytic viruses exploited for cancer therapy have been developed to selectively infect, replicate, and kill cancer cells to inhibit tumor growth. However, in some cancer cells, oncolytic viruses are often limited in completing their full replication cycle, forming progeny virions, and/or spreading in the tumor bed because of the heterogeneous cell types within the tumor bed. Here, we report that the nuclear export pathway regulates oncolytic myxoma virus (MYXV) infection and cytoplasmic viral replication in a subclass of human cancer cell types where viral replication is restricted. Inhibition of the XPO-1 (exportin 1) nuclear export pathway with nuclear export inhibitors can overcome this restriction by trapping restriction factors in the nucleus and allow significantly enhanced viral replication and killing of cancer cells. Furthermore, knockdown of XPO-1 significantly enhanced MYXV replication in restrictive human cancer cells and reduced the formation of antiviral granules associated with RNA helicase DHX9. Both in vitro and in vivo, we demonstrated that the approved XPO1 inhibitor drug selinexor enhances the replication of MYXV and kills diverse human cancer cells. In a xenograft tumor model in NSG mice, combination therapy with selinexor plus MYXV significantly reduced the tumor burden and enhanced the survival of animals. Additionally, we performed global-scale proteomic analysis of nuclear and cytosolic proteins in human cancer cells to identify the host and viral proteins that were upregulated or downregulated by different treatments. These results indicate, for the first time, that selinexor in combination with oncolytic MYXV can be used as a potential new therapy.

1 June 2023
Verified
Other
Open access
MRMasmudur Rahman
Masmudur Rahman
FOFleur van Oosterom
Fleur van Oosterom
JEJunior Ayuk Enow
Junior Ayuk Enow
MHMaksuda Hossain
Maksuda Hossain
AGAmi Gutierrez-Jensen
Ami Gutierrez-Jensen
GMGrant McFadden
Grant McFadden
Selinexor significantly enhanced MYXV infection and replication in 3D culture of human cancer cell lines. PANC-1 (A), MDA-MB435 (C), and HT29 (E) cells were treated with different concentration of selinexor for 1 hour and then infected with vMyx-GFP-TdTomato in the presence of selinexor. Fluorescence images were taken 72 or 96 hpi. Quantification of the level of GFP fluorescence as relative fluorescence units (RFU) from PANC-1 (B), MDA-MB435 (D), and HT29 (F) cells are shown. Data represent mean ± SD and n = 3. Statistically significant differences in comparison with infection without selinexor are indicated. *, P < 0.05; **, P < 0.01; ***, P < 0.001.